Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Preventing brain metastases in patients with HER2 or triple negative breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 503
Rating:

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA

Dr Alexandra Zimmer speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about ongoing clinical trials looking into the prevention and treatment of brain metastases for patients with HER2 or triple negative breast cancer - the populations who are most likely to develop brain metastases.

She explains that their results indicated that while temozolomide was found to prevent development of brain metastasis in this model, it was not effective as treatment for existing lesions.

Dr Zimmer concludes by describing the next steps of this trial and the patients that will be eligible for participation.

Categories:

· ASCO 2019

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation